Discovery may lead to new drugs to curb obesity, type 2 diabetes

(Medical Xpress)—An international study led by a researcher from The University of Western Australia for the Western Australian Institute for Medical Research (WAIMR) has produced exciting results that may lead to new drugs to treat obesity and reduce the incidence of Type 2 diabetes.

UWA Assistant Professor Vance Matthews led researchers in Melbourne, Texas and Japan to explore the effects of a protein on the surface of on conditions such as Type 2 diabetes and obesity.

Their results have appeared in the high-ranking immunology journal Immunology and Cell Biology, published by the .

Assistant Professor Matthews said the research was particularly important because had increased by 75% in the past 25 years, including an alarming increase in overweight and obese children. Insulin resistance correlated directly with obesity and could result in Type 2 diabetes, in which occurred in metabolically active body tissues.

"While my research looks at the growing problems of obesity and type 2 diabetes and how the inflammatory pathways are activated in our bodies, our discoveries also have far-reaching consequences for other diseases that involve inflammation," Assistant Professor Matthews said.

The study established that many parameters of the metabolic syndrome such as obesity and insulin resistance were significantly correlated with high levels of the metalloproteinase known as ADAM28 in .

The group explored interactions between the protein TNF-alpha – which is produced by numerous inflammatory cell types – and the metalloproteinase ADAM28. TNF-alpha is a well-known cytokine that promotes and increases the risk of Type 2 diabetes.

The study highlighted that the metalloproteinase ADAM28 may increase the release of TNF-alpha protein from the cell surface, and this effect may promote inflammation.

"Our project is very significant because it demonstrates for the first time the importance of ADAM28 in the metabolic syndrome, and further supports that metalloproteinase inhibition is a potential therapeutic target for anti-obesity agents," Assistant Professor Matthews said.

"This means that further down the track, drugs may become available to treat obesity, therefore reducing the incidence of type 2 diabetes."

add to favorites email to friend print save as pdf

Related Stories

Inflammation in body fat is not only pernicious

Mar 25, 2010

It has been a common opinion that inflammation in adipose tissue may cause insulin resistance, and thereby type 2 diabetes. However, recent research from the Swedish medical university Karolinska Institutet, published in ...

Insulin reduces inflammation caused by obesity

May 10, 2010

Recent decades have seen a huge increase in type 2 diabetes and cardiovascular disease. This is a result of people being less active and eating fattier diets, which can lead to obesity and, in turn, diabetes. In a thesis ...

Researchers identify key regulator of inflammatory response

Apr 12, 2012

(Medical Xpress) -- Researchers at Boston University School of Medicine (BUSM) have identified a gene that plays a key role in regulating inflammatory response and homeostasis. These findings could help lead to the development ...

Recommended for you

Commensal bacteria help orchestrate immune response in lung

Sep 11, 2014

Studies in mice demonstrate that signals from the bacteria that harmlessly—and often beneficially—inhabit the human gastrointestinal tract boost the immune system's ability to kill a major respiratory pathogen, Klebsiella pn ...

How age alters our immune response to bereavement

Sep 09, 2014

Young people have a more robust immune response to the loss of a loved one, according to new research from the University of Birmingham, providing insight into how different generations cope with loss.

User comments